ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,009Medicare Part D Prescriptions Filled, Including Refills

Rank: 113 out of 939

$1.6M Total Retail Price of All Prescriptions

Rank: 8 out of 939

588 Patients Receiving at Least One Drug in Part D
16%Patients 65 Years and Older
80% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

79% of this provider’s 588 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

25% of this provider’s 588 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

6% of this provider’s 1,857 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$107 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
OXYCODONE HCL 2,624 265 S2 10 1 67
METHADONE HCL 842 110 S2 2 109
OXYCODONE CONCENTRATE 703 50 S2 10 3 221
CARISOPRODOL 702 27 R 4 51
OXYCONTIN 663 77 S2 5 161
HYDROCODONE-ACETAMINOPHEN 523 82 S3 6 1
PROMETHAZINE HCL 420 39 R 7 68
ZOLPIDEM TARTRATE 412 32 8 20
MORPHINE SULFATE 389 58 S2 9 186
MORPHINE SULFATE ER 361 41 S2 10 113
AMITRIPTYLINE HCL 267 50 R 11 38
NEXIUM 260 39 12 18
LISINOPRIL 260 56 12 3
GABAPENTIN 253 24 14 11
MELOXICAM 246 42 15 14
LYRICA 191 0 16 63
TIZANIDINE HCL 184 14 17 81
FUROSEMIDE 179 18 18 7
ENDOCET 149 19 S2 19 148
FLUOXETINE HCL 147 36 20 47
HYDROMORPHONE HCL 141 0 S2 21 208
LEVOTHYROXINE SODIUM 138 16 22 4
TRAZODONE HCL 134 0 23 26
CYMBALTA 125 12 24 44
FENTANYL 125 0 S2 24 104
OMEPRAZOLE 121 24 26 5
POTASSIUM CHLORIDE 121 24 26 9
SERTRALINE HCL 120 0 28 24
PROAIR HFA 118 0 29 41
HYDROCHLOROTHIAZIDE 112 24 30 12
OXYCODONE HCL-ACETAMINOPHEN 109 19 S2 31 107
TOPIRAMATE 94 0 32 154
SIMVASTATIN 93 15 33 2
AZITHROMYCIN 77 0 34 32
VOLTAREN 74 0 35 263
SUMATRIPTAN SUCCINATE 71 0 36 282
METOPROLOL TARTRATE 71 0 36 10
CIPROFLOXACIN HCL 70 0 38 54
METFORMIN HCL 70 19 38 8
AMLODIPINE BESYLATE 69 19 40 6
CYCLOBENZAPRINE HCL 69 0 R 40 36
RANITIDINE HCL 67 19 42 35
DOXYCYCLINE HYCLATE 56 0 43 84
PAROXETINE HCL 54 0 44 70
SPIRIVA 50 18 45 73
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 22, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.